Address & contact
https://ir.compasspathways.comSpecialties
Reports that name this provider
- Psilocybin Treatment Legality in United Kingdom
- London-headquartered pharmaceutical company. Achieved primary endpoint in Phase 3 trial COMP005 for COMP360 25mg in treatment-resistant depression in June 2025 (258 participants across 32 US sites, MADRS reduction of 3.6 points vs placebo, p<0.001). Phase 3 trial COMP006 across North America and Europe also achieved primary endpoint. Plans NDA submission to FDA in Q4 2026. MHRA submission timing undetermined; FDA approval to be prioritized first.